» Articles » PMID: 30288918

Extended Follow-up for Prostate Cancer Incidence and Mortality Among Participants in the Prostate, Lung, Colorectal and Ovarian Randomized Cancer Screening Trial

Overview
Journal BJU Int
Specialty Urology
Date 2018 Oct 6
PMID 30288918
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine prostate cancer (PCa) incidence and mortality by arm in the randomized Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Patients And Methods: Patients aged 55-74 years at 10 screening centres were randomized between 1993 and 2001 to an intervention or usual care arm. Patients in the intervention arm received six annual prostate-specific antigen (PSA) tests and four annual digital rectal examinations. The patients were followed for PCa incidence and for mortality via active follow-up processes and by linkage to state cancer registries and the National Death Index. For cancers identified through active follow-up, trial abstractors recorded the mode of diagnosis (screen-detected, symptomatic, other).

Results: A total of 38 340 patients were randomized to the intervention arm and 38 343 to a usual care arm. The median follow-up for mortality was 16.9 (intervention) and 16.7 years (usual care). There were 333 (intervention) and 352 (usual care) PCa cancer deaths, giving rates (per 10 000 person-years) of 5.5 and 5.9, respectively, and a rate ratio (RR) of 0.93 (95% confidence interval [CI] 0.81-1.08; P = 0.38). The RR for overall PCa incidence was 1.05 (95% CI 1.01-1.09). The RRs by Gleason category were 1.17 (95% CI 1.11-1.23) for Gleason 2-6, 1.00 (95% CI 0.93-1.07) for Gleason 7 and 0.89 (95% CI 0.80-0.99) for Gleason 8-10 disease. By mode of detection, during the trial's screening phase, 13% of intervention arm vs 27% of usual care arm cases were symptomatic; post-screening, these percentages were 18% in each arm.

Conclusion: After almost 17 years of median follow-up, there was no significant reduction in PCa mortality in the intervention compared with the usual care arm. There was a significant increase in Gleason 2-6 disease and a significant reduction in Gleason 8-10 disease in the intervention compared with the usual care arm.

Citing Articles

Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening.

Chung D, Caverly T, Schipper M, Hofer T, Gulati R, Rose B JAMA Netw Open. 2025; 8(2):e2459766.

PMID: 39951264 PMC: 11829239. DOI: 10.1001/jamanetworkopen.2024.59766.


Evaluating the Use of Environmental and Polygenic Risk Scores to Inform Colorectal Cancer Risk-Based Surveillance Intervals.

Landy R, Katki H, Huang W, Wang D, Thomas M, Qu F Clin Transl Gastroenterol. 2024; 15(12):e00782.

PMID: 39733276 PMC: 11671055. DOI: 10.14309/ctg.0000000000000782.


Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.

Gulati R, Jiao B, Al-Faouri R, Sharma V, Kaul S, Fleishman A Ann Intern Med. 2024; 177(7):871-881.

PMID: 38830219 PMC: 11250625. DOI: 10.7326/M23-1504.


Strong association between reduction of late-stage cancers and reduction of cancer-specific mortality in meta-regression of randomized screening trials across multiple cancer types.

Dai J, Georg Luebeck E, Chang E, Clarke C, Hubbell E, Zhang N J Med Screen. 2024; 31(4):211-222.

PMID: 38797981 PMC: 11528850. DOI: 10.1177/09691413241256744.


Variation in harms and benefits of prostate-specific antigen screening for prostate cancer by socio-clinical risk factors: A rapid review.

Tesfai A, Norori N, Harding T, Wong Y, Hobbs M BJUI Compass. 2024; 5(5):417-432.

PMID: 38751945 PMC: 11090766. DOI: 10.1002/bco2.326.


References
1.
Schroder F, Hugosson J, Roobol M, Tammela T, Zappa M, Nelen V . Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384(9959):2027-35. PMC: 4427906. DOI: 10.1016/S0140-6736(14)60525-0. View

2.
Pinsky P, Blacka A, Kramer B, Miller A, Prorok P, Berg C . Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010; 7(4):303-11. DOI: 10.1177/1740774510374091. View

3.
Helgstrand J, Roder M, Klemann N, Toft B, Brasso K, Vainer B . Diagnostic characteristics of lethal prostate cancer. Eur J Cancer. 2017; 84:18-26. DOI: 10.1016/j.ejca.2017.07.007. View

4.
Pinsky P, Prorok P, Yu K, Kramer B, Black A, Gohagan J . Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2016; 123(4):592-599. PMC: 5725951. DOI: 10.1002/cncr.30474. View

5.
Chowdhury S, Robinson D, Cahill D, Rodriguez-Vida A, Holmberg L, Moller H . Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer Registry. BJU Int. 2013; 112(2):182-9. DOI: 10.1111/bju.12212. View